Innovative measures to combat rare diseases in China: The national rare diseases registry system, larger-scale clinical cohort studies, and studies in combination with precision medicine research-Reference-Cited by-同舟云学术

Innovative measures to combat rare diseases in China: The national rare diseases registry system, larger-scale clinical cohort studies, and studies in combination with precision medicine research

Published:2017 Issue:1 Volume:6 Page:1-5
ISSN:2186-361X
Container-title:Intractable & Rare Diseases Research
language:en
Short-container-title:IRDR

Author:

Song Peipei¹²,He Jiangjiang¹,Li Fen¹,Jin Chunlin¹

Affiliation:

1. Shanghai Health Development Research Center, Shanghai Medical Information Center

2. Graduate School of Frontier Sciences, The University of Tokyo

Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/irdr/6/1/6_2017.01003/_pdf

Reference24 articles.

1. 1. Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008; 371:2039-2041.

2. 2. Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Intractable and rare diseases research in Asia. Biosci Trends. 2012; 6:48-51.

3. 3. Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives. Intractable Rare Dis Res. 2012; 1:3-9.

4. 4. Ma D, Li DG, Zhang X, He L. The prevention and treatment of rare diseases in China: Opportunities and challenges. Chinese Journal of Evidence Based Pediatrics. 2011; 6:81-82. (in Chinese)

5. 5. Tang W, Makuuchi M. Intractable and rare diseases research. Intractable Rare Dis Res. 2012; 1:1-2.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scoping review of the recommendations and guidance for improving the quality of rare disease registries;Orphanet Journal of Rare Diseases;2024-05-06

2. Analysis on the Marketing Trend and Approval Lag of Imported Orphan Drugs from 2010 to 2021 in China;Therapeutic Innovation & Regulatory Science;2023-08-31

3. Long way to go: Progress of orphan drug accessibility in China from 2017 to 2022;Frontiers in Pharmacology;2023-03-08

4. 10 years of CEMARA database in the AnDDI-Rares network: a unique resource facilitating research and epidemiology in developmental disorders in France;Orphanet Journal of Rare Diseases;2021-08-04

5. A questionnaire-based study to comprehensively assess the status quo of rare disease patients and care-givers in China;Orphanet Journal of Rare Diseases;2021-07-22